98 results about "Cyclopentanes" patented technology

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a memantine derivative and a synthesis method and application thereof. The memantine derivative comprises an intermediate structural formula I, an intermediate structural formula II, an intermediate structural formula III and a structural general formula, Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1 and R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the memantine derivative provided by the invention, a memantine group is combined with an OAB-14 partial structure to change a parent nucleus structure, so that the drug activity is improved. The invention also provides a synthesis method of the compound, and the obtained compound is used for treating Alzheimer's disease and Parkinson's disease.

The invention relates to the technical field of organic synthesis, in particular to a method for synthesizing cyclopentane compounds through [3 + 2] cycloaddition reaction of aryl cyclopropane and olefin under the synergistic catalysis of bromide ions / visible light. The method comprises the following steps: in a nitrogen atmosphere, sequentially adding aryl cyclopropane, a benzyl malononitrile derivative, pyridine tribromide and a photocatalyst into a reaction solvent to obtain a mixture, stirring the mixture at the temperature of 40 DEG C under the irradiation of a 12W blue light LED lamp until the reaction is complete, and performing concentration and column chromatography purification to obtain the cyclopentane compound. The method has the advantages of mild reaction conditions, simple operation, simple and easily available raw materials and low cost.

The application provides a system and method for integrated acetaldehyde distillation and recovery, which comprises a vertically arranged main tower, the main tower is sequentially divided into a distillation section, a catalytic reaction section, a stripping section and a stripping section from top to bottom, the top of the distillation section is provided with a self-adaptive distributor and a tower top pressure controller, the catalytic reaction section comprises catalytic filler plates and a transverse liquid redistributor, and the catalytic filler plates are loaded with catalysts. The four sections of stripping, stripping, catalytic reaction and distillation are integrated in the vertical main tower, the intermediate cooling and conveying equipment are cancelled, and the investment and energy consumption are significantly reduced. The catalytic reaction section adopts the corrugated filler loaded with catalysts and cooperates with the transverse liquid redistributor, so that the liquid forms thin layer flow, the reaction residence time is effectively prolonged, and the hydrolysis decomposition rate of 2-methyl-1,3-dioxolane (MD) and the acetaldehyde recovery rate are improved.

The invention discloses a composite foaming agent, rigid polyurethane foam, a preparation method and application, and belongs to the technical field of rigid polyurethane materials. According to the technical scheme, the foaming agent comprises a first physical foaming agent, a second physical foaming agent, a chemical foaming agent and silanized cellulose nanocrystals, the first physical foaming agent is cyclopentane, the second physical foaming agent is a low-boiling-point foaming agent, and the chemical foaming agent comprises an organic amine salt compound. The foaming agent is applied to thermal insulation materials, and the problem that an existing foaming agent system cannot give consideration to heat conduction and foam strength well is solved.

The application discloses a preparation method of baricitinib, and belongs to the technical field of drug synthesis. The method comprises the following steps: firstly, 2-[1-(ethylsulfonyl)-3-azetidinyl]acetonitrile and 4-pyrazole boron pinacol ester are subjected to a Michael addition reaction to obtain 1-(ethylsulfonyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]-3-azetidine acetonitrile as an intermediate I; secondly, a protection group is introduced on the amino group of 4-chloropyrrolopyrimidine to obtain an intermediate II; finally, the intermediate I and the intermediate II are subjected to a Suzuki coupling process by adopting a method of combining a nickel pre-catalyst with a supporting ligand to obtain the baricitinib. The preparation method creatively realizes cross coupling of the baricitinib by adopting the cheap metal nickel as a catalyst, avoids the use of a heavy metal palladium catalyst, and has the advantages of low cost, low toxicity, small pollution, green environmental protection and the like.

The invention provides a crystal form VI of an acrylamide compound, and the acrylamide compound is (S)-N-(5-((6-(2-(7, 7-dimethyl-1-oxo-1, 3, 4, 6, 7, 8-hexahydro-2H-cyclopentane [4, 5] pyrrolo [1, 2-a] pyrazine-2-yl)-3-(hydroxymethyl) pyridine-4-yl)-4-methyl-3-oxo-3, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-3-(hydroxymethyl) pyridine-4-yl)-4-methyl-3-oxo-3, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-3-(2, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-4- The crystal form VI is a 2-(2, 4-dihydropyrazine-2-yl) amino)-2-(2-methyl-4-(tetrahydro-2H-pyran-4-yl) piperazine-1-yl) 5phenyl) acrylamide compound, and an X-ray powder diffraction pattern of the crystal form VI comprises diffraction peaks with the following 2 theta angle values: 8-3 + / -0.2 degrees, 13.2 + / -0.2 degrees and 18.9 + / -0.2 degrees. The crystal form VI has the advantages of good stability and low hygroscopicity, and is suitable for industrial production of bulk drugs and development of preparation prescriptions.

This invention discloses a high-strength and tough PET foam sheet and its preparation method, belonging to the field of foam material technology. It comprises the following raw materials in parts by weight: 100 parts food-grade PET resin, 3-7 parts melt reinforcing agent, 3-5 parts crystallization toughening agent, 1-3 parts in-situ fiber-forming reinforcing agent, 1-5 parts compatibility dispersant, and 8-10 parts cyclopentane. The preparation method includes: S1, mixing dried food-grade PET resin with melt reinforcing agent, crystallization toughening agent, in-situ fiber-forming reinforcing agent, and compatibility dispersant to obtain a premix; S2, melting and plasticizing the premix, injecting liquid cyclopentane for blending, and then extruding to a normal pressure environment to obtain a foam sheet blank; S3, cooling and shaping the foam sheet blank, drawing, trimming, and winding to obtain a high-strength and tough PET foam sheet. The foam sheet obtained by this invention has fine and uniform pores, possessing high flexural strength, high modulus, and high impact toughness, with comprehensive performance far exceeding that of traditional PET foam materials.

The present invention relates to the field of organic synthesis, and more particularly to a process for the preparation of cycloethers of formula (I) comprising the cyclization of compounds of formula (II) in the presence of a Lewis acid, a protic acid having a pKa of 2 or less, or a mixture thereof.

The invention relates to the technical field of chemical synthesis, in particular to a preparation method of 1-benzyl alcohol-3-alkyl bicyclo [1.1. 1] pentane, which comprises the following steps: by taking aromatic aldehyde, [1.1. 1] propeller alkane and 4-alkyl substituted Hanss ester synthesized by aldehyde as initial raw materials and dichloroethane and the like as a solvent, carrying out a reaction under the protection of inert gas to obtain 1-benzyl alcohol-3-alkyl bicyclo [1.1. 1] pentane, and separating the 1-benzyl alcohol-3-alkyl bicyclo [1.1. 1] pentane from the 1-benzyl alcohol-3-alkyl bicyclo [1.1. 1] pentane. A three-component free radical coupling reaction is carried out under the illumination condition, and a 1-benzyl alcohol-3-alkyl bicyclo [1.1. 1] pentane product is synthesized in one step. The method has the advantages of mild reaction conditions, high reaction efficiency, low cost, simplicity and convenience in operation and the like, and a new method is provided for later structural modification of diaryl methanol drug molecules.

The invention provides a foaming agent composition, premixed polyether polyol, a polyurethane composition, polyurethane foam and refrigeration equipment. The foaming agent composition comprises a foaming agent and a foam stabilizer, the foaming agent comprises bio-based cyclopentane and a CO2-based foaming agent, and the foam stabilizer comprises a bio-based siloxane-polyether copolymer. The environment-friendly property of the polyurethane foam can be improved.

This invention belongs to the technical field of drug synthesis, specifically relating to memantine derivatives, their synthetic methods, and applications. The memantine derivatives include intermediate structural formulas I, II, and III, as well as a general structural formula. The linker is a substituted or unsubstituted C6-C10 aryl group, R1 is hydrogen or a C1-C6 alkyl group, and R2 is hydrogen, a C1-C6 alkyl group, or a nitrogen-containing or nitrogen-free structural fragment, or the overall structure of R1 and R2 is an N-substituted heterocyclopentyl or heterocyclohexyl group. The memantine derivatives provided by this invention improve drug activity by combining the memantine group with the OAB-14 partial structure, thereby altering the core structure. This invention also provides a synthetic method for the obtained compounds used in the treatment of Alzheimer's disease and Parkinson's disease.

The invention discloses a temperature-resistant polyurethane thermal insulation material and a preparation method thereof. The temperature-resistant polyurethane thermal insulation material is prepared from the following raw materials: polymerized MDI, phenyl ether type polyether polyol, bifunctional polyether, a foaming agent HFO-1336mzZ, cyclopentane, an organic silicon-fluorocarbon stabilizer, a catalyst, a phosphorus-nitrogen composite flame retardant, nano silicon dioxide and a hindered phenol antioxidant. The temperature resistance of the thermal insulation material is improved to 130 DEG C from the current 105 DEG C, and the retention rate of high-temperature compression resistance is greater than or equal to 60%; the compressive strength of the foam is improved to be greater than or equal to 0.3 MPa from the current 0.2 MPa; long-term aging test and residue detection are passed, the stability of foam at 130 DEG C is confirmed, and the problems of low mechanical strength and low temperature resistance level in the current polyurethane thermal insulation material industry are effectively solved.

The invention provides a method for producing DL-2, 4-dihydroxy-3, 3-dimethyl butyric acid (DL-pantoic acid) and / or DL-3-hydroxy-4, 4-dimethyl oxacyclopentane-2-one (DL-pantolactone), in particular to a method for producing DL-2, 4-dihydroxy-3, 3-dimethyl butyric acid and / or DL-3-hydroxy-4, 4-dimethyl oxacyclopentane-2-one (DL-pantolactone) by condensation of hydroxypivalaldehyde and formyl-CoA of C1 source, in particular to a method for producing DL-2, 4-dihydroxy-3, 3-dimethyl oxacyclopentane-2-one (DL-pantoic acid) and / or DL-3-hydroxy-4, 4-dimethyl oxacyclopentane-2-one (DL-pantoic acid). The invention relates to a method for preparing 2, 4-dimethyl oxacyclopentane-2-one. The present invention also provides a genetically engineered microorganism for use in the production of DL-2, 4-dihydroxy-3, 3-dimethylbutyric acid and / or DL-3-hydroxy-4, 4-dimethyl oxacyclopentane-2-one, and also provides a genetically engineered microorganism for use in the production of DL-3-hydroxy-4, 4-dimethyl oxacyclopentane-2-one. In addition, the key enzyme has been engineered to improve its performance in the production of DL-pantoic acid or DL-pantolactone.

This invention discloses a polyurethane foam, its preparation method, and its applications. The polyurethane composition, by weight, comprises the following components: 55-100 parts polyether polyol, 0-45 parts polyester polyol, 0.7-7 parts surfactant, 3-17 parts composite catalyst, 0.7-9 parts water, 7-65 parts composite blowing agent, and isocyanate with an isocyanate index of 1.1-1.6. The composite blowing agent, by weight (100%), comprises 9-70% pentane, 3-75% decafluorocyclopentane, and 0-35% butane. The blowing agents used in this invention produce a synergistic effect, reducing the defects caused by using individual physical blowing agents alone. This allows customers to obtain polyurethane products with superior foam performance, providing better choices for ultra-low energy consumption and inner liner materials in the industry.

Alcohol based unleaded automotive racing fuels, using blends of four basic chemical components, including ethanol, methanol, toluene, and isopentane and / or cyclopentane. Mixtures provide increased power, and better charge cooling than conventional racing gasolines, whether leaded or unleaded. The claimed racing fuel blends do not include gasoline, isooctane, or alkylate fractions common to alcohol-gasoline mixtures such as E85 alcohol based fuels. The novel fuel blends claimed can be manufactured from commonly available pure chemical components, and make possible distributed manufacture of automotive racing fuels.

The invention belongs to the technical field of lubricants, and discloses a lubricant containing Guerbet alcohol derivatives and a preparation method and application thereof. The lubricant is prepared from the following components in parts by weight: 2 to 6 parts of Guerbet alcohol derivative, 0.2 to 1 part of sulfurized isobutylene, 0.05 to 0.3 part of tungsten disulfide nanosheet, 0.01 to 0.1 part of surface modified fullerene, 0.5 to 1.5 parts of triisopropanolamine borate, 80 to 95 parts of 2-octyl-dodecyl cyclopentane, 0.3 to 0.8 part of antioxidant and 0.1 to 0.5 part of antirust agent. The Guerbet alcohol derivative is an ester derivative of Guerbet alcohol; the surface modified fullerene is obtained by modifying fullerene by using dodecyl mercaptan and azodiisobutyronitrile. When ester synthesized from isostearyl alcohol is used as an ester derivative of Guerbet alcohol, the lubricant still has good lubricating performance. Furthermore, the high-temperature-resistant and high-pressure-resistant oxidation performance is good.

The invention relates to a supramolecular semi-interpenetrating polymer network electrolyte and a preparation method and application thereof.The supramolecular semi-interpenetrating polymer network electrolyte is prepared from, by weight, 150-300 parts of polytetrahydrofuran, 150-300 parts of 18-crown ether-6, 40-60 parts of dicyclohexylmethane 4, 4 '-diisocyanate, 2, 2'-(1, 4-phenyl)-bis [4-(4-hydroxybutyl)-1, 3, 4-trimethyl-1, 3, 4-trimethyl-1, 3, 4-trimethyl-1, 3, 4-trimethyl-1, 3, 4-trimethyl-1, 3, 4-trimethyl-1, 3, 4-trimethyl-1, 3, 4- The composite material is prepared from the following components in parts by weight: 32 to 48 parts of 1, 2-dioxaborolane], 1 to 1.2 parts of a catalyst, 5.5 to 8.5 parts of an end-capping reagent, 1500 to 2500 parts of 1, 3-dioxolame, 500 to 840 parts of lithium bis (trifluoromethylsulfonyl) imide, 23 to 38 parts of scandium trifluoromethanesulfonate and 15 to 25 parts of a cross-linking agent. According to the invention, a functional thermoplastic polyurethane elastomer-rotaxane is introduced into a polydioxolame matrix to form a supramolecular semi-interpenetrating network structure, so that concentration polarization and growth of lithium dendrites can be inhibited, and the cycling stability is improved.

The present disclosure relates to oral dosage forms comprising an antiviral nucleoside and one or more excipients, wherein the oral dosage form is a tablet. The antiviral nucleoside is selected from a prodrug of beta-D-N (4)-hydroxycytidine (I), such as 2-methylpropionic acid {(2R, 3S, 4R, 5R)-3, 4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3, 4-dihydropyrimidin-1 (2H)-yl] oxacyclopentane-2-yl} methyl ester)-compound (A), or a pharmaceutically acceptable salt, tautomer or prodrug thereof. (I) (A)

This application discloses an organic compound and its uses, as well as an organic electroluminescent device, relating to the field of organic electroluminescent materials technology. The organic compound has the structural formula shown in formula (I): L1 and L2 are each independently selected from single bonds, substituted or unsubstituted C6-C30 aryl groups, substituted or unsubstituted C5-C30 heteroaryl groups, and do not contain triazine or its derivatives, carbazole or its derivatives, or anthracene or its derivatives; Ar1 ​​and Ar2 are each independently selected from substituted or unsubstituted C6-C30 aryl groups, substituted or unsubstituted C5-C30 heteroaryl groups, or formed into a ring with adjacent atoms; R1 and R2 are each independently selected from substituted or unsubstituted methyl groups, substituted or unsubstituted tert-butyl groups, substituted or unsubstituted cyclopentyl groups, substituted or unsubstituted hexyl groups, or substituted or unsubstituted adamantyl groups, and the substituent is deuterium when substituted; the hydrogen in the organic compound can optionally be replaced with deuterium. This organic compound can significantly improve the performance of organic electroluminescent devices.

The present application relates to a kind of n-hexane-methylcyclopentane energy-saving rectification separation system and process, belong to separation process technical field;The separation system includes extractive distillation column and extractive agent regenerator, the bottom of the extractive distillation column is communicated with heat pump reboiler and extractive agent regenerator middle portion by circulating pump respectively;The heat pump reboiler is communicated with the lower part of extractive distillation column by heat exchange reboiler;The bottom of the extractive agent regenerator is connected with heat pump evaporator by the heat exchange reboiler, the heat pump evaporator is communicated with the heat pump reboiler by heat pump compressor, the heat pump reboiler is sequentially connected with supercooling cooler and pressure reducing valve, the pressure reducing valve is communicated with the heat pump evaporator by pipeline.The high-temperature regenerated extractive agent produced by extractive agent regenerating unit is directly used as heat source to provide part of heating for extractive distillation column in the present application, realize the step-by-step utilization of high-temperature extractive agent waste heat, significantly reduce the external heating load of extractive distillation column, reduce system energy consumption.

This invention belongs to the field of catalysis technology, specifically relating to a method for preparing cyclopentane derivatives from furan compounds. The method includes the following steps: mixing a furan compound, a copper-based catalyst, a halogen modifier, and a first solvent, and reacting them under a hydrogen atmosphere; the halogen modifier is at least one selected from sodium chloride, sodium bromide, potassium chloride, potassium bromide, chlorobenzene, and bromobenzene. This invention, by adding a halogen modifier to the catalytic system, introduces halogen components onto the surface of the copper-based catalyst to construct Cu-halogen active centers, achieving highly selective rearrangement of furan compounds into cyclopentane derivatives under relatively mild conditions, while significantly suppressing condensation side reactions, improving carbon utilization efficiency, and reducing dependence on the type of support.

The present invention aims to provide a novel compound which has an OX2R agonist activity.The present invention relates to a cyclopentane compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof has an agonist activity on OX2R and is useful as an agent for the treatment of sleep disorders involving OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to physical diseases, hypersomnia due to psychiatric disorders, hypersomnia due to drugs or substances, circadian rhythm sleep-wake disorder, insufficient sleep syndrome and long sleep) or the like.

This invention discloses a zinc oxide capsule, a polypropylene antibacterial coating, its preparation method, and its application. The preparation method of the zinc oxide capsule includes: S1. mixing zinc oxide, emulsifier, initiator, triethylamine, and water to obtain a core material mixture; S2. mixing acrylic acid monomers and an organic phase change material to obtain a wall material mixture; S3. mixing the core material mixture and the wall material mixture, and heating to react, thereby obtaining the zinc oxide capsule; in step S2, the acrylic acid monomers contain acrylic acid, resveratrol, and allylcyclopentane in a mass ratio of 1:(0.1-1.5):(0.1-1). The zinc oxide capsule prepared by this invention can simultaneously improve the antibacterial effect, adhesion, wear resistance, and aging resistance of the polypropylene antibacterial coating.

This invention proposes a ratiometric fluorescent probe molecule for detecting peroxynitrite, its preparation method, and its application, aiming to solve a problem in the technical field of fluorescent sensing materials. The ratiometric fluorescent probe molecules of this invention are HPIP-T-BnB and HPIP-K-BnB. The structural formulas of HPIP-T-BnB and HPIP-K-BnB are: [Insert structural formula here], and the structural formulas of HPIP-K-BnB are: [Insert structural formula here]. The preparation method includes the following steps: 4'-(diphenylamino)-4-(imidazo[1,2-a]pyridin-2-yl)-[1,1'-biphenyl]-3-ol or 4'-(9H-carbazole-9-yl)-4-(imidazo[1,2-a]pyridin-2-yl)-[1,1'-biphenyl]-3-ol undergoes a nucleophilic substitution reaction with 2-(4-(bromomethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxoborhecyclopentane to obtain HPIP-T-BnB and HPIP-K-BnB. The probes prepared in this invention can detect ONOO⁻ with high selectivity, high sensitivity, and quantification, and have been successfully applied to ratiometric fluorescence imaging of exogenous and endogenous ONOO⁻ in live cells. This provides a reliable and crucial tool for mechanism research and drug development in related diseases.

The invention provides a preparation method of ((1R, 3S)-3-hydroxycyclopentyl) tert-butyl carbamate, which comprises the following steps: (1) mixing (R)-3-oxocyclopentane carboxylic acid with alkali, diphenyl azide phosphate and tert-butyl alcohol for reaction to obtain an intermediate; and (2) mixing the intermediate with a chiral catalyst and borane for reaction to obtain ((1R, 3S)-3-hydroxycyclopentyl) tert-butyl carbamate. The preparation method provided by the invention has the advantages of cheap and easily available raw materials, simple process operation, safe and controllable production and high optical purity of the target product, and can meet the requirements of industrial production.

To provide a method for enabling efficient high-yield production of an oxadisilacyclopentane compound.SOLUTION: A method for producing an oxadisilacyclopentane compound represented by the general formula (4) comprises reacting a bisilylethane compound having an acyloxy group represented by the general formula (1) with an amine compound such as allylamine. (In the formulas, R1 to R4 each independently represent an unsubstituted C1-4 monovalent hydrocarbon group; and R5 represents H, or a substituted or unsubstituted C1-20 monovalent hydrocarbon group.)SELECTED DRAWING: None

The invention relates to a nanoparticle for use as a drug carrier and the synthesis method of this nanoparticle. In the invention, magnesium / aluminium (Mg / AI) mucoadhesive thiolated layered double hydroxide (nLDHT) nanoparticles are thiolated with L-cysteine and / or thioglycolic acid and / or 2-iminothiolane hydrochloride and / or glutathione and / or N-acetyl cysteine and / or 3-mercaptopropionic acid and / or 6- mercaptohexanoic acid. Thus, nLDHT interacts with the mucin on the surface of the targeted mucosal tissue for a longer period of time and acts with fewer side effects in the target tissues.